Pinetree Therapeutics nears $47M Series B Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 23 October, 2025

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

presented by The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

spotlight Frequent flyers: Top drugmakers’ private jets descended on DC more than 120 times this year, data show

news Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions Exclusive: AstraZeneca-partnered Pinetree nears $47M Series B for protein degraders Moderna’s CMV vaccine fails Phase 3 study, ending long-shot prevention effort Exclusive: In the race to build virtual cells, AI bio Tahoe open-sources its own model

Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB

Bring your rare disease drug to the Japanese market — join PMDA officials to map the path forward. Find out how — get your spot.

endpoints pharma Arcturus’ stock halved after mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delay Alkermes to acquire Avadel and its narcolepsy drug for up to $2.1B Major pharma companies spent more on lobbying in third quarter Corrected: Alector’s GSK-partnered dementia drug flunks Phase 3, plots to halve workforce Amy Gleason, a top Trump health official, calls for more access to patient data Genmab was one of three bidders before inking $8B Merus acquisition Thermo Fisher, Danaher stand to gain from drugmakers’ onshoring efforts 10x Genomics sues DNA giant Illumina over patents

in case you missed it 1. Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data 2. Exclusive: Fast Track Initiative closes $130M venture fund to bridge science between US and Japan 3. Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront 4. Ipsen to buy ImCheck for €350M to get 'superfamily' of immunotherapies 5. Terns ditches obesity pill and pivots to cancer after mid-stage letdown 6. News Briefing